IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2.
Activation of invariant natural killer T (iNKT) cells with CD1d-restricted T-cell receptor (TCR) ligands is a powerful means to modulate various immune responses. However, the iNKT-cell response is of limited duration and iNKT cells appear refractory to secondary stimulation. Here we show that the CD94/NKG2A inhibitory receptor plays a critical role in down-regulating iNKT-cell responses. Both TCR and NK-cell receptors expressed by iNKT cells were rapidly down-modulated by priming with alpha-galactosylceramide (alpha-GalCer) or its analog OCH [(2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-N-tetracosanoyl-2-amino-1,3,4-nonanetriol)]. TCR and CD28 were re-expressed more rapidly than the inhibitory NK-cell receptors CD94/NKG2A and Ly49, temporally rendering the primed iNKT cells hyperreactive to ligand restimulation. Of interest, alpha-GalCer was inferior to OCH in priming iNKT cells for subsequent restimulation because alpha-GalCer-induced interferon gamma (IFN-gamma) up-regulated Qa-1b expression and Qa-1b in turn inhibited iNKT-cell activity via its interaction with the inhibitory CD94/NKG2A receptor. Blockade of the CD94/NKG2-Qa-1b interaction markedly augmented recall and primary responses of iNKT cells. This is the first report to show the critical role for NK-cell receptors in controlling iNKT-cell responses and provides a novel strategy to augment the therapeutic effect of iNKT cells by priming with OCH or blocking of the CD94/NKG2A inhibitory pathway in clinical applications.
Ota
Tsuyoshi
T
Department of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Takeda
Kazuyoshi
K
Akiba
Hisaya
H
Hayakawa
Yoshihiro
Y
Ogasawara
Kouetsu
K
Ikarashi
Yoshinori
Y
Miyake
Sachiko
S
Wakasugi
Hiro
H
Yamamura
Takashi
T
Kronenberg
Mitchell
M
Raulet
David H
DH
Kinoshita
Katsuyuki
K
Yagita
Hideo
H
Smyth
Mark J
MJ
Okumura
Ko
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000378:metabolism*; D025461:Feedback, Physiological / Q000502:physiology; D005699:Galactosylceramides / Q000494:pharmacology; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D007156:Immunologic Memory; D007371:Interferon-gamma / Q000235:genetics / Q000378:metabolism*; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism*; D037181:Lectins, C-Type / Q000378:metabolism*; D008024:Ligands; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D055654:NK Cell Lectin-Like Receptor Subfamily C; D051920:NK Cell Lectin-Like Receptor Subfamily D; D011971:Receptors, Immunologic / Q000378:metabolism*; D055607:Receptors, Natural Killer Cell
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D005699:Galactosylceramides; D015395:Histocompatibility Antigens Class I; C527057:Klrc1 protein, mouse; C497870:Klrd1 protein, mouse; D037181:Lectins, C-Type; D008024:Ligands; D055654:NK Cell Lectin-Like Receptor Subfamily C; D051920:NK Cell Lectin-Like Receptor Subfamily D; C032907:Q surface antigens; D011971:Receptors, Immunologic; D055607:Receptors, Natural Killer Cell; C493154:alpha-galactosylceramide; D007371:Interferon-gamma
Nat Rev Immunol. 2004 Mar;4(3):190-8
15039756
J Exp Med. 2004 Feb 2;199(3):417-22
14744994
Nat Immunol. 2004 Jun;5(6):590-6
15122252
Trends Immunol. 2004 Sep;25(9):471-6
15324739
J Immunol. 2004 Sep 15;173(6):3693-706
15356115
Cell. 1994 Nov 18;79(4):649-58
7525079
Immunol Rev. 1995 Oct;147:67-89
8847081
Eur J Immunol. 1996 Aug;26(8):1801-6
8765024
Annu Rev Immunol. 1997;15:535-62
9143699
J Immunol. 1997 Aug 1;159(3):1418-28
9233639
Science. 1997 Nov 28;278(5343):1626-9
9374463
Immunity. 1998 Sep;9(3):345-53
9768754
J Exp Med. 1998 Nov 16;188(10):1841-8
9815261
J Exp Med. 1999 Feb 1;189(3):587-92
9927520
J Exp Med. 1999 Apr 5;189(7):1121-8
10190903
J Immunol. 1999 Nov 1;163(9):4647-50
10528160
Science. 2004 Dec 3;306(5702):1786-9
15539565
J Exp Med. 1999 Dec 20;190(12):1801-12
10601355
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):740-4
10639149
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5498-503
10792025
Eur J Immunol. 2000 Jul;30(7):1919-28
10940881
J Exp Med. 2000 Sep 4;192(5):741-54
10974039
Immunol Today. 2000 Nov;21(11):573-83
11094262
Nat Immunol. 2000 Dec;1(6):459-60
11101862
J Immunol. 2001 May 15;166(10):6012-8
11342617
Eur J Immunol. 2001 Jun;31(6):1720-7
11385616
Nature. 2001 Oct 4;413(6855):531-4
11586362
J Immunol. 2001 Oct 15;167(8):4180-6
11591738
J Exp Med. 2001 Oct 15;194(8):1179-86
11602646
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):868-73
11782535
Curr Opin Immunol. 2002 Apr;14(2):165-71
11869887
Nat Rev Immunol. 2002 Aug;2(8):557-68
12154375
Clin Cancer Res. 2002 Dec;8(12):3702-9
12473579
Immunity. 2003 Jan;18(1):41-51
12530974
Annu Rev Immunol. 2003;21:483-513
12543936
J Immunol. 2003 Jun 15;170(12):5815-9
12794105
J Immunol. 2003 Aug 15;171(4):1715-21
12902470
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10913-8
12960397
J Immunol. 2003 Oct 15;171(8):4020-7
14530322
J Immunol. 2003 Nov 1;171(9):4539-51
14568927
Blood. 2004 Jan 15;103(2):383-9
14512316
J Immunol. 2004 Jan 15;172(2):943-53
14707067
Int Immunol. 2004 Feb;16(2):241-7
14734609
Nat Immunol. 2004 May;5(5):516-23
15098030